this should have a market cap of 100 million +, page-32

Hi J8,

For 'a boy from the bush' your articulation is quite remarkable. Congratulations on your win today.

"Sovaldi is only approved for treatment in combination with Int/Rib. It reduces the time of the treatment from twelve months to six in most cases. It also improves the SVR12 rate."

Your comments are quite correct however I think Gilead's 'Electron' study has more recently shown that the dual interferon-free regimen of Sovaldi plus ribavirin can produce a SVR24 rate of 100% for untreated patients with HCV genotypes 2 and 3.

I certainly don't think the potential for Biotron is over-valued @ $38m today, however that's not to say there is no competition in the field, nor the opportunity to partner with any competition.

Imo.